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Human serum albumin (HSA) is an important regulator of the pharmacokinetic properties of bioactive
compounds. Phycocyanobilin is a blue tetrapyrrole chromophore of C-phycocyanin with proven health-
promoting activities. Despite its structural similarity to bilirubin, the conformation it adopts in aqueous
solution is different and the pigment is more soluble than bilirubin. The aim of our study was to examine
binding of phycocyanobilin for HSA and to investigate its competition with bilirubin. Based on a
computational approach, we demonstrated two putative high-affinity binding pockets on HSA of virtually
identical energies for the neutral and anion forms of bilirubin, but with slightly favorable predictions for anion
forms of phycocyanobilin. Computational prediction of phycocyanobilin pKa values suggested a monoanion
form to be the most stable form at physiological conditions. The computationally predicted binding sites for
phycocyanobilin were identical to the two previously identified binding sites for bilirubin (subdomains IB and
IIA). Results obtained by protein and pigment fluorescence measurements, circular dichroism, and
competition experiments confirmed high affinity (binding constant of 2.2  106 M1 at 25 C), stereo-
selective binding of phycocyanobilin M-conformer to HSA and its competition with bilirubin, warfarin and
hemin. Our experimental data confirm that phycocyanobilin binds to IB and IIA binding site of HSA with an
affinity similar to bilirubin. In conditions characterized by an increased bilirubin plasma concentration, or
intake of drugs binding to IB or IIA binding site, pharmacokinetics of phycocyanobilin may also be changed.Introduction
The intensive blue color of photosynthetic cyanobacteria Spir-
ulina arises from C-phycocyanin, the most abundant protein of
this blue-green alga with exceptional nutritional properties.1 It
has been documented that the C-phycocyanin's health-
benecial activities are exerted by its chromophore, phycocya-
nobilin.2,3 The chemical structure of phycocyanobilin is highly
similar to that of bile pigment bilirubin and its precursor,
biliverdin (Fig. 1A).
Extraordinary binding capacity of human serum albumin
(HSA) for various ligands makes this protein an importantxcellence for Molecular Food Sciences,
e, Studentski trg 12-16, 11000 Belgrade,
: +381 11 2184330; Tel: +381 11 3336657
allurgy – Center for Chemistry, University
Serbia
and Biotechnology, National Hellenic
tinou Ave., 11635 Athens, Greece
tion (ESI) available. See DOI:
o this work.
hemistry 2015regulator of the pharmacokinetic properties of drugs and a
model protein to study interactions with natural bioactive
compounds. HSA is a single polypeptide globular protein
composed of three homologous a-helical domains (I, II and
III), each containing two subdomains (A and B). Binding sites
for most aromatic and heterocyclic ligands are mainly located
within two hydrophobic pockets in subdomains IIA (Sudlow's
site I) and IIIA (Sudlow's site II).4,5 Sudlow's site I is known as
the warfarin–azapropazone site.4 The characteristic feature of
this site is binding of the bulky heterocyclic anion ligand with
a negative charge localized in the middle of the molecule.
Drugs binding in this site include warfarin, valproate and
azapropazone. Site II is known as the indole–benzodiazepine
site, and ligands that bind to this region include ibuprofen,
urbiprofen and diazepam.4 There are also drugs that bind to
both sites on HSA.4,6
The biosynthetic form of the bilirubin molecule
(4Z,15Z-bilirubin IXa), which is lipophilic and insoluble in
water at neutral pH, is transported in blood plasma by serum
albumin to the liver where it is converted to a water-soluble
glucuronide.7 Bilirubin is normally present in plasma at low
concentration (5–17 mM) but, when conjugation of bilirubin isRSC Adv., 2015, 5, 61787–61798 | 61787
Fig. 1 (A) Chemical structure of phycocyanobilin, bilirubin and
biliverdin; (B) schematic representation of opposite helical confor-
mations (M or P) of phycocyanobilin: half of the molecules drawn by
bold are above the plane of the paper. Ring substituents were omitted
for clarity; (C) conformations of differently ionized (neutral, mono-
anionic and dianionic) forms of phycocyanobilin.
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View Article Onlinedecient, the unconjugated pigment accumulates in the circu-
lation and extravascular tissue. HSA acts as a physiological
buffer for bilirubin as it prevents the transfer of bilirubin from
blood to tissues and impairs the development of bilirubin
encephalopathy, a serious pathological condition.8 Evidence
from circular dichroism (CD) studies shows that binding of
bilirubin to HSA is enantioselective, since the P-enantiomer is
bound preferentially.9 However, biliverdin IXa, a biological
precursor of bilirubin, binds to HSA preferentially as
M-enantiomer.10
The biosynthetic 4Z,15Z-isomer of bilirubin binds with high
affinity (the binding constant of 107 to 108 M1) to a single site
on HSA.11,12 There are also one or two secondary sites with
affinities that are at least tenfold lower.8,13 This issue is
complicated by the photoisomerization of bilirubin, a process
that is relevant to the clinical management of metabolic disor-
ders involving the pigment. The conversion of 4Z,15Z-bilirubin
to 4Z,15E-bilirubin-IXa (4Z,15E-bilirubin) by photosensitization
results in the formation of a geometric isomer that has a lower
binding affinity for HSA but higher water solubility, which
permits it to be excreted more easily than the precursor
4Z,15Z-bilirubin.14
Despite numerous studies, there is controversy about the
localization of the primary high-affinity bilirubin-binding site
on albumin. A crystallographic study located binding site for
bilirubin photoisomer 4Z,15E-bilirubin within the subdomain
IB. This modeled conformation has M-type helicity, which is
opposite to the P-type helicity observed in CD measurements of
4Z,15Z-bilirubin bound to HSA.15 In line with this, numerous
studies pointed to the hydrophobic pocket of the subdomain IIA61788 | RSC Adv., 2015, 5, 61787–61798as the primary high-affinity binding site for bilirubin.8,16Hemin,
another precursor of bilirubin, predominantly binds to site IB
on HSA.17,18
Another controversy about bilirubin is its charge state at
the physiological pH. The most recent studies demonstrated
that despite the experimental data that supported lower pKa
values of the two carboxylic groups in the molecule, the
charge state of bilirubin is neutral until pH 8, i.e. at physio-
logical pH of 7.2–7.4.19 The molecule exists in a tight
hydrogen-bonded conformation that prevents ionization of
its carboxyl groups and reduces solubility in aqueous solu-
tions. No similar data exist for bilirubin-analog phycocyano-
bilin. Similarly to biliverdin, phycocyanobilin cannot adopt
ridge-tile conformation of bilirubin because of the presence
of the double bond that prevents rotation and also give rise to
quite different spectral characteristics of the intensive blue
colored pigment.20
Our work, based on a computational approach for studying
interactions between HSA, bilirubin and bilirubin-analog
phycocyanobilin, demonstrated two putative high-affinity
binding pockets on HSA for bilirubin and phycocyanobilin,
that could accommodate both neutral and anion forms of both
molecules. The binding sites were identical to the two previ-
ously identied binding sites for bilirubin (sites IB and IIA).
Results obtained by protein and pigment uorescence
measurements, circular dichroism, as well as bilirubin-
displacement experiments, conrmed high affinity, enantio-
selective binding of phycocyanobilin M-conformer to HSA and
its competition with bilirubin, warfarin and hemin for the
binding on HSA.
Materials and methods
Materials
HSA (purity $ 97%), bilirubin (purity $ 98%), warfarin (purity
$ 98%) and hemin (purity$ 98%) were purchased from Sigma-
Aldrich (Tauirchen, Germany) and used without further
purication. HSA solutions were prepared in 20 mM Tris buffer,
pH 7.4 and the protein concentration was determined using an
extinction coefficient of 35 700 M1 cm1 at 280 nm. Bilirubin,
warfarin and hemin were dissolved in 99.9% dimethyl sulfoxide
(DMSO) to make 4 mM stock solution. Phycocyanobilin was
isolated and puried from commercial Hawaiian Spirulina
Pacica powder (Nutrex, USA) and characterized as previously
described.21 Stock phycocyanobilin solutions were obtained by
dissolving dry pigment in anhydrous methanol. Phycocyanobi-
lin concentration was determined by measuring absorbance
of aliquots diluted in conc. HCl/MeOH (1 : 19; v/v) at 680 nm
(3 ¼ 37 900 M1 cm1).22 For all experiments, stock solutions of
HSA, phycocyanobilin, bilirubin, warfarin and hemin were
diluted with 20 mM Tris buffer, pH 7.4 and nal concentrations
of methanol and DMSO in the protein–ligand mixtures did not
exceed 1% (v/v). Phycocyanobilin, bilirubin and hemin stock
solutions and mixtures were constantly kept in the dark. All
other chemicals were of analytical reagent grade and Milli-Q
water (Millipore, Molsheim, France) was used throughout the
experiments.This journal is © The Royal Society of Chemistry 2015
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View Article OnlineComputational details
pKa values of phycocyanobilin were estimated using isodesmic
reaction approach,23 i.e. calculation of free energy of proton
exchange reaction in water solution (the reaction schemes (I)
and (II)) with bilirubin as reference specie.
PCBH2(soln) + BRH(soln)
/ PCBH(soln)
 + BRH2(soln) (I)
PCBH(soln)
 + BR(soln)
2/ PCB(soln)
2 + BRH(soln)
 (II)
The structures of neutral phycocyanobilin (in most stable
helical all-Z, all-syn conformation) and bilirubin (in the
biosynthetic 4Z,15Z “ridge-tile” conformation) and corre-
sponding anions were fully optimized with B3LYP density-
functional theory method, using standard 6-311++G(d,p) basis
set and characterized as energy minima by the absence of
imaginary frequencies. The solvent effects have been taken into
account in all geometry optimizations and energy calculations
by using the SMD model.24 All quantum chemical calculations
were performed with Gaussian09 program package.
Molecular modeling of the phycocyanobilin/bilirubin–HSA
complex was performed using the 3D crystal structure of HSA
(PDB ID: 1BM0) extracted from the Protein Data Bank.25 All
water molecules were removed from the protein structure. Since
the hydrogen data is missing, protonation state of each titrat-
able amino acid was estimated with nite difference Poisson–
Boltzmann continuum electrostatics model as implemented in
H++ 3.0 program.26 Missing amino acids from N- and
C-terminus were built and the whole protein structure was
optimized in CHARMM program (version c35b1) using the
CHARM22 protein force eld.27 Optimization of HSA structure
was carried out in 2000 optimization steps (1000 steps with
steepest-descent algorithm followed by 1000 steps with
Newton–Raphson algorithm).
The optimized structures of neutral ligands and corre-
sponding anions were taken from pKa calculations described
earlier. Optimized structures of protein and ligands were
further subjected to AutoDockTools (version 1.5.6. Sep_17_14)
program for docking preparation. All protein residues were kept
rigid. For phycocyanobilin ligand all three double bond were
kept rigid in Z conformation, while the three single bonds of the
exocyclic methine bridges were set to be rotational. Similarly,
bilirubin double bonds 4 and 15 (Fig. 1A) were kept in Z
conformation and all single bonds were set to be rotational. A
grid box, with the dimensions 28  28  28 A˚, was used to
accommodate the ligand to move freely during docking run. In
order to cover whole surface and volume of HSA a grid box was
moved over the rectangular matrix containing protein with
points 8 A˚ apart, so the total of 1188 docking runs were
produced for every ligand. The docking studies were carried out
with AutoDockVina program (version 1.1.2).28 To increase the
probability for nding the minimum during docking run
exhaustiveness parameter in AutoDock Vina program was set to
100. From each docking run 9 binding modes with highest
scoring function were kept for further analysis.
Analysis of data from PDB recognized a total of 7 fatty acid
binding sites (FA1-FA7), 6 other ligands binding sites (IB, IIA,This journal is © The Royal Society of Chemistry 2015IIA-IIB, IIIA, IIIB and cle) and two drug binding sites (drug site
1 and drug site 2).29 Based on crystallographic data, ligand type
and ligand binding site(s), a subset of 16 HSA crystal structures
of total of 96 structures found in PDB was chosen for further
data analysis (Table S1 of ESI†). Overlapping amino acid resi-
dues that can be included in binding both phycocyanobilin and
other ligands were collected (Table S2 of ESI†). Amino acid
residues from binding sites IB and IIA and selected ligands are
presented in the Fig. S1 (in ESI†).
In order to verify validity of used molecular modeling
method, an extensive docking study on selected HSA crystal
structures was conducted. The docking method was the same as
described above, with two changes: (i) the structure of the
protein was not optimized and (ii) in order to save the compu-
tational time, the exhaustiveness parameter in AutoDockVina
program was set to 10. To verify the accuracy of the method, a
re-docking simulation was performed for every ligand found in
the selected crystal structures, except for myristic acid.
Obtained data have shown that AutoDockVina program is
performing very well in nding the proper binding site for
studied ligands. RMSD values between center of the mass of
docked and crystalographically found ligand positions are
presented in Table S3 (in ESI†).
For the 19 out of 21 ligands found in selected crystal struc-
tures in re-docked analyses AutoDockVina was able to nd the
proper position and orientation of the ligand and RMSD values
are lower than 1 A˚ (Table S3 and Fig. S2A of ESI†). For the two
remaining ligands (site IIIB in 2VUF and site IB in 4LA0) a
proper position for the ligand was found but with different
orientation (Fig. S2B of ESI†), resulting in a somewhat larger
RMSD values (Table S3 of ESI†).
The inuence of conformational changes in protein due to
ligand binding on HSA affinity to bind phycocyanobilin was
examined. In this simulation, all crystalographically found
ligands and fatty acids coordinates were deleted from crystal
structures and docking studies were conducted on ligand-free
protein using monoanionic form of phycocyanobilin.
To examine an inuence of bound fatty acids or other
ligands on phycocyanobilin binding to HSA, nal docking study
on 6 selected crystal structures with myristic acid and 14
structures with bound other ligands was done.Fluorescence spectroscopy measurements
All uorescence data were obtained on FluoroMax®-4 spectro-
uorometer (HORIBA Scientic, Japan) under thermostated
conditions, with the width of the excitation and emission slit
both adjusted at 5 nm.
Binding of phycocyanobilin to HSA was studied by the uo-
rescence quenching titration method using the intrinsic uo-
rescence of HSA as a probe, at constant protein (0.375 mM) and
various ligand concentrations (0 to 1.5 mM). The steady-state
uorescence spectra were measured at 25, 30 and 37 C. The
excitation wavelength was set at 280 nm (excitation of the Trp
and Tyr), and the emission spectra were read at 290 to 400 nm.
The appropriate blanks corresponding to the various phyco-
cyanobilin in buffer concentration were subtracted to correctRSC Adv., 2015, 5, 61787–61798 | 61789
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View Article Onlinebackground of uorescence. Fluorescence intensities were cor-
rected for the absorption of excited light and the re-absorption
of emitted light due to the inner-lter effect, according to
relation:30
Fc ¼ F010(Aem+Aex)/2 (1)
where F0 is measured uorescence, Fc is corrected uorescence,
Aex and Aem are absorbance of quencher at excitation and pick
emission wavelength (340 nm), respectively.
To determine the type of quenching, Stern–Volmer's (SV)
constants were calculated at different temperatures using the
equation:30
F0
F
¼ 1þ kqso½Q ¼ 1þ KSV½Q (2)
where F0 and F are protein emission uorescence at 340 nm
without and with addition of ligand, respectively, kq is
quenching rate constant of the biomolecule, so is average life-
time of the biomolecule without quencher (108 s), [Q] is total
quencher (phycocyanobilin) concentration, and KSV is SV
quenching constant. KSV can be calculated on the basis of SV
plots.
The estimation of the association (binding) constant (Ka),
and number of binding sites (n) of HSA–phycocyanobilin system
was done using equation:31
log
F0  F
F
¼  n log 1
½L  ½P F0  F
F0
þ n log Ka (3)
where [P] and [L] are total concentration of protein (HSA) and
ligand (phycocyanobilin), respectively, and Ka is the binding
constant.
The synchronous uorescence characteristics of HSA–phy-
cocyanobilin complex were recorded at two different scanning
intervals: Dl 15 nm (Tyr residues excitation) and Dl 60 nm (Trp
residue excitation), where Dl ¼ lEM  lEX.
The thermodynamic parameters were determined from the
equations:
ln Ka ¼  DH
RT
þ DS
R
(4)
DG ¼ DH  TDS (5)
where Ka is the binding constant, R is universal gas constant
(8.313 J mol1 K1), DG is free energy change, DH is enthalpy
change, and DS is entropy change. The values of DH and DS
were calculated from the slope and intercept of linear plot of
ln Ka versus 1/T.
Enhancing of phycocyanobilin (1 mM) emission uorescence
by HSA (up to 2 mM) was recorded in the range of 470 to 650 nm,
where excitation wavelength was set to 460 nm. Affinity constant
for ligand binding to protein was calculated from enhancement
of phycocyanobilin uorescence at 547 nm, using the
equation:32
1
DF
¼ 1
DFmax
þ 1
Ka DFmax ½P (6)61790 | RSC Adv., 2015, 5, 61787–61798where DF is the change of phycocyanobilin uorescence inten-
sity in the presence and absence of HSA; DFmax is the maximal
change of uorescence intensity, Ka is the binding constant,
and [P] is the concentration of HSA.
Bilirubin displacement from HSA–bilirubin complex by
phycocyanobilin was investigated by recording synchronous
uorescence spectra in the range 490–650 nm, where Dl was 56
nm. Equimolar mixture of HSA and bilirubin (4 mM) was titrated
with phycocyanobilin in the range of phycocyanobilin to
HSA–bilirubin complex molar ratio 0–2.5. Phycocyanobilin
displacement from HSA–phycocyanobilin complex by bilirubin
was also investigated by recording synchronous uorescence
spectra in the range 590–750 nm, where Dl was 87 nm. Equi-
molar mixture of HSA and phycocyanobilin (2 mM) was titrated
with bilirubin in the range of bilirubin to HSA–phycocyanobilin
complex molar ratio 0–2.5.
In order to conrm that phycocyanobilin and bilirubin bind
to warfarin–azapropazone binding site on HSA, equimolar
mixtures of HSA and phycocyanobilin or HSA and bilirubin
(2 mM) were titrated with warfarin in the range of warfarin to
HSA–phycocyanobilin/bilirubin complex molar ratio 0–10.
Fluorescence spectra were recorded in the range 480–585 nm,
whereas the excitation wavelength was 460 nm. Also, equimolar
mixture of HSA and warfarin (0.25 mM) was titrated with
phycocyanobilin or bilirubin up to ligand-complex molar ratio
2, and synchronous uorescence spectra were obtained in the
range 365–400 nm, where Dl was 64 nm. Finally, to conrm that
phycocyanobilin and bilirubin bind to IB binding site on HSA,
equimolar mixtures of HSA and phycocyanobilin or HSA and
bilirubin (2 mM) were titrated with hemin in the range of hemin
to HSA–phycocyanobilin/bilirubin complex molar ratio 0–2.5.
Fluorescence spectra were recorded in the range 480–585 nm,
whereas the excitation wavelength was 460 nm.
For the determination of binding sites, titration of phyco-
cyanobilin to HSA in absence and presence of site markers
(warfarin and hemin) were performed as a competitive experi-
ment. 0.5 mM HSA was pre-incubated with 0.5 mM site markers
and phycocyanobilin was gradually added to the HSA-site
markers up to four-fold molar excess. Phycocyanobilin binding
constants were calculated using eqn (3) as described above.
All experiments were replicated at least twice, with duplicate
repeated measures within each replication.CD spectroscopy measurements
The CD measurements were carried out on Jasco J-815 spec-
tropolarimeter (Jasco, Tokyo, Japan). For the measurements in
the near-UV and visible region (260–750 nm), with two scans
averaged for each CD spectra, concentrations of HSA and phy-
cocyanobilin were 18 mM, and for displacement experiments
bilirubin concentrations were 18 mM and 36 mM.Results and discussion
Calculation of phycocyanobilin pKa values
Chemical structures of intensively blue-colored phycocyanobi-
lin, blue-green biliverdin and orange-yellow bile pigmentThis journal is © The Royal Society of Chemistry 2015
Fig. 2 Molecularmodeling of phycocyanobilin/bilirubin bound human
HSA. The domains in ribbon model of protein HSA (PDB ID: 1BM0) are
color codes as follows: I, orange; II, green; III, turquoise blue. Structural
models depicting two potential binding sites for monoanionic form of
phycocyanobilin (A) and bilirubin (B) to HSA: bound phycocyanobilin
and bilirubin are shown in purple and yellow color space filling
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View Article Onlinebilirubin are highly similar (Fig. 1A). Moreover, P- andM-helical
enantiomers of phycocyanobilin are presented in Fig. 1B.
There is a lot of controversy in the literature about ionization
state of two bilirubin carboxylic groups at physiological condi-
tions.19 No similar experimental or theoretical data exist for
phycocyanobilin, but based on structural similarity and prox-
imity of carboxylate groups in biliverdin, a structural analog of
phycocyanobilin, it is more likely that pKa values of phycocya-
nobilin will not be similarly high.
Our data conrmed high pKa values (pKa1¼ 8.1 and pKa2¼ 8.4)
recently predicted for bilirubin.19 It is evident from the published
data and our computational predictions that ridge-tile confor-
mation adopted by bilirubin in aqueous solutions presents an
obstacle to ionization of its carboxylic groups. Contrary to bili-
rubin, phycocyanobilin's most stable conformation is helicoidal
and enables easy ionization of the rst carboxylic group of the
pigment. pKa1 value predicted by quantum chemical calculations
using isodesmic reaction approach for phycocyanobilin is 2.4.
Formation of the hydrogen bond between ionized and protonated
group (Fig. 1C) retracts ionization of the second carboxylic group
and the estimated pKa2 is 9.6. Thus, the most compact and the
most stable conformation of phycocyanobilin in aqueous solu-
tions and at physiological pH is itsmonoanion form, in which one
hydrogen atom is bridging two carboxylate groups (Fig. 1C).representation, respectively. The best docked results for phycocya-
nobilin (represented using a stick model) complexed to HSA:
subdomain IB (C) and subdomain IIA (D). The secondary structure of
the protein is shown, and important neighboring amino acids residues
within 3.5 A˚ are labeled. Hydrogen atoms were omitted for clarity. The
figures have been generated using PyMOL (http://www.pymol.org/).Docking analysis of high-affinity binding sites for
phycocyanobilin and bilirubin on HSA
Six different docking studies were performed, either with fully
protonated phycocyanobilin and bilirubin molecules or with
their mono and dianionic forms. Analysis of the docking results
predicted two potent binding sites (subdomains IB and IIA) for
phycocyanobilin on HSA molecule (Fig. 2A), and they overlap
with those previously described of bilirubin (Fig. 2B). Estimated
binding energies are slightly higher for bilirubin binding
comparing to phycocyanobilin and for both anionic pigment
forms than for the neutral molecules. It can be observed that
virtually identical energies were estimated for the neutral and
anion forms of bilirubin, but with slightly favorable predictions
for anion forms of phycocyanobilin (Table 1).
It is well known that binding of various ligands induce
conformational changes in HSA. Therefore, we have examined
the inuence of different HSA conformations on phycocyano-
bilin binding, using 16 HSA crystal structures. Two proposed
phycocyanobilin binding sites (IB and IIA) are most probable
binding sites regardless of the protein conformation, although
the estimated binding energies are somewhat inuenced by
protein conformation and positions of amino acids side chains;
for IB site binding energies are between 8.4 and 10.8 kcal mol1
and for IIA between 8.5 and 10.5 kcal mol1 (Table S3 of ESI†).
The rst high-affinity binding site for phycocyanobilin is
located at the IB subdomain of the protein and is composed of
the residues from helices H8, H9, H10 and polypeptide “strap”
(residues 110–117) connecting subdomains IB and IA. The
binding site is in L-shaped geometry, and phycocyanobilin
ligand structure with highest binding energy adopts M confor-
mation (Fig. 2C). Interior of the binding site is mainlyThis journal is © The Royal Society of Chemistry 2015hydrophobic with main contribution from Leu-115, Pro-118,
Met-123, Ile-142, Phe-157 and Leu-182. There are three posi-
tively charged amino acids at the entrance of the binding site:
Arg-114, Arg-117 and Arg-186. Our docking study indicates
Arg-114 and Arg-117 are involved in formation of salt bridges/
hydrogen bonds with propionic groups from phycocyanobilin
molecule, while Arg-186 is more likely to form hydrogen bond
with lactam ring carbonyl oxygen. Further, polar groups from
Tyr-138, Glu-141, Arg-145, Tyr-161 and Asp-183 can be involved
in hydrogen bonding interactions with the ligand. It is inter-
esting to note the potential for stacking between aromatic rings
of Phe-134 and Tyr-138 and pyrrole rings of the phycocyanobilin
(Fig. 2C). This binding site is in the close proximity to the
binding site for 4Z,15E-bilirubin-IXa isomer previously deter-
mined by crystallographic analysis, with marked similarity in
amino acid residues binding pattern.15
It is interesting to note that FA1 binding site for myristic acid
and proposed phycocyanobilin IB binding site share almost the
same amino acid residues lining the cavity wall of subdomain
IB (PDB code 1BJ5).33 Indeed, presence of myristic acid at FA1
binding site preclude phycocyanobilin binding to IB site, while
its presence at the other FA binding sites does not inuence
binding of phycocyanobilin (Table S4 of ESI†). IB binding site is
not large enough to accommodate ligand and myristic acid, so
the ligand is pushed away towards the cle binding siteRSC Adv., 2015, 5, 61787–61798 | 61791
Table 1 Binding energies (kcal mol1) for HSA–phycocyanobilin and HSA–bilirubin interactions
HSA subdomain
Phycocyanobilin form Bilirubin form
Neutral Monoanionic Dianionic Neutral Monoanionic Dianionic
IB 10.8 10.9 11.3 11.1 11.1 11.3
IIA 10.7 10.8 11.1 11.0 11.1 11.2
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View Article Online(Fig. S3A of ESI†). Binding of other ligands (such as hemin,
4Z,15E-bilirubin-IXalpha, fusidic acid) occupying IB site also
prevent phycocyanobilin binding (Table S5 of ESI†).
The second high-affinity binding site is located in the
hydrophobic cavity formed by the helices H1–H5 of the IIA
subdomain (Fig. 2D). This cavity is formed by the side chains of
the amino acids Phe-211, Trp-214, Leu-219, Phe-223 (from H1),
Val-235, Leu-238 (from H2), Leu-260, Ile-264 (from H3) and Ile-
290, Ala-291 (from H5). Similarly to the rst binding site, this
binding site is L-shaped with phycocyanobilin bound as
M-conformer. Both highly polar/anionic propionic groups of the
phycocyanobilin ligand are oriented towards upper part of the
helix H10 (residues 194–206) from IB subdomain. Lys-195 and
Lys-199 residues (from helix H10) are most probably positively
charged. His-242 is involved in formation of salt bridges/
hydrogen bonds with propionic groups from the ligand. Other
charged residues found in the binding site (Arg-218, Arg-222
and Arg-257) are involved in hydrogen bonding with carbonyl
or NH group of lactam ring. Based on our docking analysis,
there is a potential for head to tail stacking interaction between
Trp-214 and one of the phycocyanobilin ligand pyrrole rings
(Fig. 2D). Above-described data for phycocyanobilin docking to
subdomain IIA fully correspond to proposed structure of bili-
rubin binding site for this subdomain on HSA molecule.16
Although phycocyanobilin position and binding energy in
IIA binding site is somewhat altered by the presence of the
myristic acid at the FA7 site, docking simulation predicts this
binding site to be most probably binding site (Fig. S3B of ESI†).
The presence of myristic acid on all other HSA binding sites
does not inuence phycocyanobilin binding to IIA site (Table S4
of ESI†), while binding of other selected ligands occupying IIA
site differently inuence phycocyanobilin binding. For the most
of the structures, existence of ligands at IIA binding site,
including R- and S-warfarin, prevents docking of phycocyano-
bilin. In the case of some ligands (azapropazone, azapropazone
and indomethacin or lysophasphatidylethanolamine) there is
still enough space to accommodate phycocyanobilin and
pigment binding is not prevented (Table S5 and Fig. S4 of ESI†).
Especially interesting are docking results for the HSA crystal
structure with two ligands (indomethacine and azapropazone;
PBD code 2BXK) and phycocyanobilin docked in the same cavity
(Fig. S4B of ESI†), conrming how large and versatile HSA IIA
binding site is.8
Our data thus evidenced that putative binding sites on HSA
for phycocyanobilin are in close proximity to binding sites
experimentally demonstrated for bilirubin (Fig. S2C of ESI†).
The charge state of both pigments does not inuence binding61792 | RSC Adv., 2015, 5, 61787–61798mode or estimated binding energy that also suggests high
affinity binding for phycocyanobilin. Furthermore, computa-
tional predictions provided a stereo-selective binding of M-
conformer of phycocyanobilin to HSA.
Earlier approach to mutate HSA and determine critical
amino acids for bilirubin binding within the domain IIA was
not successful. The approach was based on predictions of
dianionic form binding to HSA, thereby K195M, K199M, F211V,
W214L, R218M, R222M, H242V, R257M mutations were
performed within the site IIA and did not inuence the binding
affinity of bilirubin to HSA.8 It was proposed that the binding
mode for bilirubin may be dynamic. Multiple pattern binding
mode is attributable to the formation of a exible 4Z,15Z-bili-
rubin–HSA complex, and no single crucial binding mode exists,
but multiple interactions are ongoing between 4Z,15Z-bilirubin
and HSA.
Another study employing creation of phage-displayed HSA
mutants demonstrated that the binding affinity of 4Z,15Z-bili-
rubin for wild-type domain I (residues 1–186) was signicantly
lower than that for wild-type domain II. Furthermore,
4Z,15Z-bilirubin, when bound to domain I, adopts an unusual
M-conformation that is quite different from the typical
P-conformation that it adopts when binding to domain II and
full-length HSA.11Phycocyanobilin binds to HSA and quenches protein intrinsic
uorescence
Quenching of HSA intrinsic uorescence, mostly contributed by
Trp-214 at subdomain IIA, is useful tool for characterization of
ligand binding to HSA.34 HSA has only one Trp residue and
18 Tyr residues.35 Fig. 3A shows the uorescence emission
spectra of HSA in the absence and presence of phycocyanobilin.
Upon excitation of HSA at 280 nm, protein exhibits a strong
uorescence emission with a maximum at 340 nm that was
quenched upon phycocyanobilin addition in a concentration-
dependent manner. Furthermore, a signicant blue shi is
observed with increasing phycocyanobilin concentration
(Fig. 3A), suggesting that the intrinsic uorophore of HSA is
placed in amore hydrophobic environment aer the addition of
phycocyanobilin.36 The blue shi could also be explained by a
preferential quenching of the Trp-214 residues by phycocyano-
bilin, that would remain only Tyr residues to contribute to HSA
uorescence. Indeed, intensive quenching of Trp-214 uores-
cence by phycocyanobilin makes more visible contribution of
Tyr-263 to protein uorescence pick (“shoulder” at 308 nm;
Fig. 3A). This tyrosine residue is the closest tyrosine to SudlowThis journal is © The Royal Society of Chemistry 2015
Table 2 The Stern–Volmer quenching constants (KSV), bimolecular
quenching constants (kq), binding constant (Ka) and the number of
binding sites (n) on the HSA–phycocyanobilin system at different
temperaturesa
T
(C)
Eqn (2) Eqn (3)
KSV
(M1)  106
kq
(M1 s1)  1014 S.D.
Ka
(M1)  106 n S.D.
25 1.23 1.23 0.024 2.24 0.97 0.041
30 0.92 0.92 0.018 1.80 0.83 0.037
37 0.69 0.69 0.021 1.23 0.85 0.040
a S.D. is the standard deviation.
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View Article Onlinesite I located in subdomain IIA, not completely buried inside
the protein.37
Fig. 3B represents the SV plots for the HSA uorescence
quenching by phycocyanobilin at three different temperatures.
It can be seen that the quenching constant (slope of curves)
decreases with increasing temperature (Table 2), and the values
of kq are greater than the limiting diffusion rate constant of the
biomolecule (2  1010 M1 s1) indicating a static type of
quenching.38
Phycocyanobilin binds to HSA with the binding affinities of
2.2  106 M1 (at 25 C) and approximate 1 : 1 stoichiometry
(Table 2; Fig. S5 in ESI†). In comparison with drugs and other
exogenous compounds, observed phycocyanobilin association
constant for HSA of the order of magnitude 106 M1 is among
the largest,39 and comparable to that of bilirubin (5  106 M1
at 25 C).40The binding mode between HSA and phycocyanobilin
In order to conrm bindingmode of phycocyanobilin to HSA we
calculated the thermodynamic parameters, enthalpy (DH) and
entropy (DS) of interactions. The temperature dependence ofFig. 3 (A) Emission spectra (excitation at 280 nm) of HSA (0.375 mM) in
the presence of different concentrations of phycocyanobilin (0, 0.2,
0.4, 0.6, 0.8, 1.0, and 1.5 mM, for curves a to g, respectively). Dot line
curve shows the emission spectrum of 1.5 mM phycocyanobilin; (B)
Stern–Volmer plots of HSA fluorescence quenched by phycocyano-
bilin at three different temperatures and pH 7.4. Error bars represent
the standard deviation.
This journal is © The Royal Society of Chemistry 2015the HSA–phycocyanobilin binding constant was studied at
three different temperatures (25, 30 and 37 C): the plot of ln Ka
vs. 1/T (Fig. S6 in ESI†) enabled the determination of DH
(39.2 kJ mol1) and DS (9.7 J mol1 K1).
Large negative value for DH and much smaller, but also
negative value for DS, at all temperatures, suggests that
formation of complex is enthalpy driven and hydrogen bonding
plays a signicant role in the binding mode.41 Similar binding
mode was previously demonstrated for HSA–bilirubin system,
with a decrease in binding constant for increasing salt
concentration, implicating that hydrogen bonds and electro-
static interactions are the main factor in the binding of
bilirubin to its primary site on HSA.13 Moreover, a numerous
hydrogen bonds between phycocyanobilin and HSA proposed
by docking analysis at both binding sites identied in our study
(Fig. 2) are in agreement with experimentally determined ther-
modynamic data.Binding of phycocyanobilin to HSA changes environment of
Trp-214 residue
Synchronous uorescence spectroscopy gives information
about the molecular environment in the vicinity of the uo-
rophore functional groups. When Dl between the excitation
wavelength and the emission wavelength were set at 15 or
60 nm, the synchronous uorescence could provide informa-
tion of the tyrosine or tryptophan residues environment in HSA,
respectively.42 In contrast to Tyr residues (Fig. 4A), a small blue
shi (from 343 to 340 nm) in the maximum emission wave-
length of Trp residues was observed (Fig. 4B). This indicates the
polarity around the Trp residue is decreased, while the micro-
environment around the tyrosine residues did not signicantly
change during the binding process. It has also been shown in
Fig. 4C that the slope of SV quenching plot was sharper when Dl
was 60 nm, conrming that protein uorescence decrease upon
phycocyanobilin binding mostly originates from the quenching
of critical Trp-214 residue.43
Phycocyanobilin efficiently quenched Trp and placed it in a
more hydrophobic environment (as demonstrated in quenching
experiments, as well as in synchronous spectra), and this effect
arise from p-stacking interaction between Trp-214 and
phycocyanobilin.RSC Adv., 2015, 5, 61787–61798 | 61793
Fig. 4 Synchronous fluorescence spectra of HSA (0.375 mM) with (A)
Dl ¼ 15 nm (Tyr) and with (B) Dl ¼ 60 nm (Trp) in the presence of
increasing concentration of phycocyanobilin (0–1.5 mM) for curves a to
g, respectively; (C) the Stern–Volmer quenching plots of HSA
synchronous fluorescence by phycocyanobilin: Dl ¼ 60 nm for Trp
and Dl ¼ 15 nm for Tyr. Error bars represent standard deviation.
Fig. 5 (A) Effect of HSA addition (1, 1.25, 1.5, 1.75, and 2 mM, for curves
a to e, respectively) on the emission spectra of 1 mM phycocyanobilin
(excitation at 460 nm). Dot line curve: the emission spectrum of 1 mM
phycocyanobilin; (B) near UV-visible CD spectra of phycocyanobilin
(18 mM) in the presence (black solid line) and absence of 18 mM HSA
(dot line). Gray line represents CD spectrum of 18 mM HSA.
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View Article OnlineBinding of phycocyanobilin to HSA induces enhancement of
pigment uorescence and negative Cotton effect in CD
spectrum of phycocyanobilin
Phycocyanobilin is a chromophore that shows characteristic
UV-visible, CD and uorescence spectra. It is known that upon
interaction of its analog bilirubin with serum albumin, there is
a signicant enhancement of weak intrinsic uorescence and a
red shi of the emission maximum.44,4561794 | RSC Adv., 2015, 5, 61787–61798Fig. 5A represents the uorescence spectra of phycocyano-
bilin aer excitation at 460 nm. Upon HSA addition, strong
uorescence of phycocyanobilin further increases with the
maximum emission shi towards higher wavelengths (from 518
to 541 nm). Calculated binding constant from the enhancement
of uorescence was 1.1  105 M1 (Fig. S7†).
Phycocyanobilin exists mostly in ZZZsss (all Z, all syn)
conformation, adopting a cyclic-helical conformation with a
right-hand (P) and le-hand (M) conformers in equilibrium.46
Therefore, at pH 7.4 phycocyanobilin does not show optical
activity. HSA addition generates a positive band at 370 nm and a
negative band at 620 nm in the CD spectrum of phycocyano-
bilin, producing so-called negative Cotton effect (Fig. 5B). This
result indicates that shiing of equilibrium between P and M
conformers, as a consequence of binding of one of them for a
protein, causes optical activity of phycocyanobilin. Similarly to
our results on phycocyanobilin, the consequence of bilirubin
and biliverdin M conformers binding for HSA produces a
negative Cotton effect.10,11,47 The right-handed, P-helical
conformer of biliverdin displays a negative Cotton effect near
380 nm and a positive Cotton effect around 650 nm.48 Therefore,
our result proves binding of phycocyanobilin M-conformer toThis journal is © The Royal Society of Chemistry 2015
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View Article Onlinethe protein and these results are in line with the computational
predictions.
Analysis of the CD spectral changes during NaBH4 reduction
of biliverdin bound noncovalently to HSA indicates an in situ
inversion of the predominantly M-helicity verdin conformation
to afford a predominantly P-chirality bilirubin bound to the
protein.10 It is thus proposed that the binding site for bilirubin/
biliverdin may be exible enough to support transition of
M-helical verdin conformer to le-helical P-enantiomer of
bilirubin.Phycocyanobilin competes with bilirubin, and site markers
warfarin and hemin for binding to HSA
Taking into account the structural similarity, the results of
docking studies, and experimentally determined binding
affinity of phycocyanobilin to HSA, an additional study was
performed to conrm identity of binding site(s) for phycocya-
nobilin and bilirubin on HSA molecule.
In these experiments, we rstly monitored various spectral
changes of HSA–bilirubin complex aer phycocyanobilin addi-
tion and vice versa. Excitation of HSA–bilirubin and HSA–phy-
cocyanobilin complexes at 460 nm induces strong emission
maxima at relatively close wavelength at 516 and 547 nm,
respectively. Therefore, synchronous uorescence spectra were
obtained with Dl 56 nm and Dl 87 nm, for monitoring emission
of HSA–bilirubin and HSA–phycocyanobilin complexes,
respectively. When Dl is set at 56 nm, bilirubin in the complex
with HSA shows strong emission peak at 523 nm. Free bilirubin
at these conditions has negligible emission (Fig. 6A). Upon
phycocyanobilin addition, peak intensity markedly decreases
suggesting increases of free bilirubin concentration due to
phycocyanobilin displacement of bilirubin from its binding site
on HSA. This result also supports binding constants similarity
of bilirubin and phycocyanobilin for HSA. When Dl is set at
87 nm, emission peak of HSA–phycocyanobilin complex
appears at 618 nm. At this wavelength, HSA–phycocyanobilin
complex has notably larger emission in comparison to free
phycocyanobilin (Fig. 6B). Upon bilirubin addition, peak
intensity decreases, indicating that free phycocyanobilin
concentration increases as bilirubin induces displacement of
phycocyanobilin from its binding site on HSA.
Bilirubin in the complex with HSA shows optical activity,
with the positive and negative band in near UV-visible CD
spectra at 460 and 410 nm, respectively.16 From Fig. 6C it can be
seen that the addition of bilirubin in a solution containing
HSA–phycocyanobilin complex leads to a reduction of the
ellipticity at 370 nm, as well as the decrease in ellipticity at 620
nm. Knowing that both bands originate from phycocyanobilin
bound to HSA and phycocyanobilin itself does not show optical
activity (Fig. 6C) these data additionally support phycocyano-
bilin displacement by bilirubin from its complex with HSA.
The ligands (probes) that specically bind to a known region
on HSA are oen used in competition experiments with the
tested substance to facilitate the identication of the binding
site. X-ray crystallography studies unequivocally uncovered that
warfarin is probe for subdomain IIA49 and hemin is probe forThis journal is © The Royal Society of Chemistry 2015subdomain IB.50Upon warfarin addition to HSA–phycocyanobilin
in 1 : 1 molar ratio, small decrease of emission maximum
appears, wherein at tenfold excess warfarin induces only slight
additional decrease of peak intensity (Fig. 6D). In contrast, phy-
cocyanobilin efficiently displace warfarin from HSA–warfarin
equimolar complex (Fig. 6E). Under the same experimental
design, similar results can be observed in the case of warfarin
competition with bilirubin for HSA and vice versa (Fig. S8 and S9
of ESI†). The results may be explained by the fact that warfarin
has much smaller binding constant for HSA (3.8  105 M1 at
25) in comparison to bilirubin (5.0  106 M1 at 25) and phy-
cocyanobilin (2.2  106 M1; Table 2). Re-docking simulation on
1HA2 and 2BXD structures resulted in R- and S-warfarin binding
energies of 9.6 and 8.8 kcal mol1, respectively, 1.2–2.0 kcal
mol1 lower values (Table 1) then phycocyanobilin binding
energy in IIA site. Titration of equimolar HSA–phycocyanobilin
mixture with hemin (binding constant of 0.9  106 M1 at 25)
causes powerful uorescence signal quenching of the pigment in
a complex with a protein (Fig. 6F). In fact, the same observation
can be seen aer bolus addition of hemin into equimolar mixture
of HSA with bilirubin (Fig. S10†). This suggests that these ligands
bind not only to subdomain IIA in the Sudlow site 1 but also to
subdomain IB, the respective binding site of warfarin and hemin.
In order to compare the effect of site markers on
HSA-phycocyanobilin binding, phycocyanobilin binding
constants in the presence of site markers were calculated using
eqn (3), and compared to the original value. The phycocyano-
bilin binding constant (2.2  106 M1) was only slightly
decreased in the presence of warfarin (1.6  106 M1) or hemin
(2.0  106 M1). However, in the presence of both markers
binding constant was notably reduced (0.9  105 M1). These
results suggests that in the presence of warfarin phycocyanobilin
can bind freely to IB subdomain binding site, but to compete
with warfarin for IIA binding site resulting in apparently slightly
reduced binding constant. Similarly, the presence of hemin in
system leaves free binding site IIA resulting also in slightly
decreased phycocyanobilin binding constant for HSA. When
both of the markers are present phycocyanobilin competes with
them for both available high-affinity binding sites on protein,
leading to signicantly reduced binding constant. In addition,
although warfarin has one order of magnitude lower Ka then
hemin (see previous paragraph), it is more efficient in reducing
phycocyanobilin binding constant for HSA in comparison to
hemin, indicating that phycocyanobilin affinity to binding site
IIA is somewhat higher than for binding site IB.
It has previously been shown that bile pigment structurally
similar to phycocyanobilin, biliverdin, also competes with bili-
rubin, but only for the high affinity binding site.48 Previous data
have shown that an addition of a competitor ligand (drug
specic for high affinity site) to bilirubin–HSA complex caused a
redistribution of the bilirubin among the other sites which lead
to a less efficient competition for binding to the protein.16
Taken together, our results of displacement experiments
further advocated identity of binding sites for phycocyanobilin
and bilirubin on HSA, and propensity of phycocyanobilin to
efficiently compete for the binding to the major plasma carrier
protein.RSC Adv., 2015, 5, 61787–61798 | 61795
Fig. 6 (A) Quenching of HSA–bilirubin complex (4 mM both) by phycocyanobilin (0, 2, 4, 6, 8 and 10 mM, for curves a to f, respectively) using
synchronous fluorescence spectroscopy, Dl 56 nm. Dash line curve: 4 mM HSA in presence of 4 mM phycocyanobilin. Dot line curve: 10 mM
bilirubin. Dash-dot line curve: 10 mM phycocyanobilin; (B) quenching of HSA–phycocyanobilin complex (2 mM both) by bilirubin (0, 1, 2, 3, 4 and
5 mM, for curves a to f, respectively) using synchronous fluorescence spectroscopy,Dl 87 nm. Dash line curve represents 2 mMHSA in presence of
2 mM bilirubin. Dot line curve: 2 mM phycocyanobilin. Dash-dot line curve represents 10 mM bilirubin; (C) decreasing of HSA–phycocyanobilin
complex (18 mM both) ellipticity by bilirubin (0, 18 and 36 mM for curves a to c, respectively). Dot line curve shows the CD spectrum of 18 mM
bilirubin in presence of 18 mMHSA. (D) Quenching of HSA–phycocyanobilin complex (2 mM both) by warfarin (0, 2, 4, 6, 8 and 20 mM, for curves a
to f, respectively) (excitation wavelength 460 nm). Dash line curve: 2 mM HSA in presence of 20 mM warfarin. Dot line curve: 2 mM phycocya-
nobilin; (E) quenching of HSA–warfarin complex (0.25 mM both) by phycocyanobilin (0, 0.125, 0.25, 0.375, and 0.5, for curves a to e, respectively)
using synchronous fluorescence spectroscopy, Dl 64 nm. Dash line curve: 0.25 mM HSA. Dot line curve: 0.25 mM warfarin. Dash-dot line curve:
0.25 mM HSA in presence of 0.25 mM phycocyanobilin; (F) quenching of HSA–phycocyanobilin complex (2 mM both) by hemin (0, 1, 2, 3, 4, and
5 mM, for curves a to f, respectively) (excitation wavelength 460 nm). Dot line curve: 2 mM phycocyanobilin, dash line curve: 2 mMHSA in presence
of 2 mM hemin.
61796 | RSC Adv., 2015, 5, 61787–61798 This journal is © The Royal Society of Chemistry 2015
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View Article OnlineConclusions
Our work, based on a computational approach to studying
interactions between HSA, bilirubin and bilirubin-analog phy-
cocyanobilin, demonstrated two putative high-affinity binding
pockets on HSA for bilirubin and phycocyanobilin, of virtually
identical energies for the neutral, mono- and dianionic forms of
both molecules.
The binding sites were identical to the two previously iden-
tied binding sites for bilirubin (at subdomain IB and sub-
domain IIA). Results obtained by protein and pigment
uorescence measurements, circular dichroism, as well as
bilirubin-displacement experiments, conrmed high-affinity,
enantioselective binding of phycocyanobilin M-conformer to
HSA and its competition with bilirubin, warfarin and hemin for
the binding on HSA. Ionizing state of ligands (neutral vs.
monoanion vs. dianion) appeared to have no marked impact on
binding to HSA. The present results provide valuable informa-
tion for the transportation and distribution of phycocyanobilin
in vivo, which may be of importance for the understanding of its
proposed numerous benecial effects. In addition, our data
suggest that in conditions characterized by an increased bili-
rubin plasma concentration, or intake of drugs binding to IB or
IIA HSA binding site, pharmacokinetics of phycocyanobilin may
also be changed.Conflict of interest
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